for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Fagron NV

FAGRO.BR

Latest Trade

15.12EUR

Change

-0.17(-1.11%)

Volume

54,057

Today's Range

15.02

 - 

15.45

52 Week Range

13.11

 - 

21.56

As of on the Euronext Brussels ∙ Minimum 15 minute delay

Pricing

Previous Close
15.29
Open
15.45
Volume
54,057
3M AVG Volume
2.53
Today's High
15.45
Today's Low
15.02
52 Week High
21.56
52 Week Low
13.11
Shares Out (MIL)
72.86
Market Cap (MIL)
1,115.56
Forward P/E
18.76
Dividend (Yield %)
0.83

Next Event

Q4 2021 Fagron NV Earnings Release

Latest Developments

More

Fagron NV Says Disclosure Of Received Notification Of The Capital Group Companies And NN Group NV

Fagron Q3 Revenue At 142.4 Million Euros, Up 5.4%

Fagron H1 REBITDA Down 11% TO EUR 56.0 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Fagron NV

Fagron NV, formerly Arseus NV, is a Belgium-based company that is active in the healthcare sector. It operates as a research and development (R&D) scientific pharmaceutical compounding supplier and operates through four segments: The Fagron Specialty Pharma Services segment comprises personalized medication that is produced in the Company's compounding facilities; the Fagron Trademarks segment encompasses concepts and formulations developed by the Company's research and development (R&D) team; Fagron Essentials comprises pharmaceutical raw materials, equipment and supplies for pharmacies, and the HL Technology segment includes the development and production of precision components and orthopedic tools for dental and medical professionals.

Industry

Biotechnology & Drugs

Contact Info

Venecoweg 20A

9810

Belgium

+32.80.012880

https://fagron.com/

Executive Leadership

Koen Hoffman

Independent Chairman of the Board Representing AHOK BVBA

Rafael Padilla

Chief Executive Officer, Member of the Executive Committee, Director

Karin de Jong

Chief Financial Officer, Executive Director, Member of the Executive Committee

Constantijn van Rietschoten

Chief Communications Officer, Member of the Executive Committee

Marc Coucke

Director Representing Alychlo NV

Key Stats

2.00 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2018

0.5K

2019

0.5K

2020

0.6K

2021(E)

0.6K
EPS (EUR)

2018

0.590

2019

0.570

2020

0.820

2021(E)

0.850
Price To Earnings (TTM)
20.36
Price To Sales (TTM)
2.01
Price To Book (MRQ)
3.88
Price To Cash Flow (TTM)
12.94
Total Debt To Equity (MRQ)
120.79
LT Debt To Equity (MRQ)
111.48
Return on Investment (TTM)
9.38
Return on Equity (TTM)
6.90

Latest News

Latest News

BRIEF-Fagron Says Alychlo Completed A Private Sale Of Shares In Company

* REG-ALYCHLO HAS SUCCESSFULLY COMPLETED A PRIVATE SALE OF SHARES IN FAGRON

BRIEF-Fagron To Propose 2019 Dividend Of 0.08 Euro Per Share

* GLOBAL UNCERTAINTY REGARDING IMPACT OF COVID-19 IN 2020 REQUIRES COST CONTROL AND DISCIPLINED CAPITAL ALLOCATION

BRIEF-Fagron FY Net Profit Up 30.3% At EUR 55.7 Million

* REG-FAGRON REALISES TURNOVER GROWTH OF 13.4%; REBITDA INCREASES TO € 117.0 MILLION

Belgium's Fagron to expand into Mexico with Cedrosa buy

Belgian pharmaceutical ingredients group Fagron NV said on Monday it was acquiring Central de Drogas, S.A. de C.V. (Cedrosa) in a 352 million Mexican pesos ($18.39 million) cash deal to expand further its presence in Latin America.

Belgium's Fagron to expand into Mexico with Cedrosa buy

Belgian pharmaceutical ingredients group Fagron NV said on Monday it was acquiring Central de Drogas, S.A. de C.V. (Cedrosa) in a 352 million Mexican pesos ($18.39 million) cash deal to expand further its presence in Latin America.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up